"I keep thinking, what would have happened if there had been any more delays?" Rachael Misfud said Rachael Misfud / SWNS (2) A mom of four said she was put on a nine-month waiting list to remove what ...
A systematic review found that bilateral salpingectomy is associated with roughly an 80% reduction in risk for the serous ...
A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, ...
Researchers at Karolinska Institutet have uncovered a unique ability of a special subtype of natural killer cells in the immune system, called adaptive NK cells, to remember ovarian tumors and ...
A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women facing platinum-resistant ovarian cancer (PROC). Researchers evaluated a novel ...
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial ...
Avmapki Fakzynja is a type of targeted medicine called a tyrosine kinase inhibitor (TKI). TKIs are used to treat many different types of cancers, including ovarian cancer. Avmapki Fakzynja is ...
University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for providing insights into molecular changes linked to early ovarian cancer ...
Sofetabart mipitecan is an antibody-drug conjugate consisting of an Fc-silent, folate receptor alpha specific monoclonal antibody attached to an exatecan payload.
A recent study published in Genes & Diseases reveals a novel role of XPR1 in promoting ovarian cancer growth by regulating autophagy and MHC-I expression. The research, conducted by scientists from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results